Elicio Therapeutics (NASDAQ:ELTX) Releases Earnings Results, Misses Expectations By $0.16 EPS

Elicio Therapeutics (NASDAQ:ELTX) posted its earnings results on Monday. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.16), FiscalAI reports.

Elicio Therapeutics Price Performance

Shares of NASDAQ ELTX traded up $1.66 during mid-day trading on Monday, reaching $11.57. The company had a trading volume of 316,800 shares, compared to its average volume of 131,168. The company has a 50-day moving average price of $11.37 and a two-hundred day moving average price of $9.51. The stock has a market cap of $216.40 million, a PE ratio of -4.42 and a beta of 1.12. Elicio Therapeutics has a 1-year low of $5.15 and a 1-year high of $14.93. The company has a current ratio of 2.38, a quick ratio of 2.38 and a debt-to-equity ratio of 5.75.

Analyst Ratings Changes

ELTX has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Elicio Therapeutics in a research note on Friday, April 24th. LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a report on Wednesday, April 15th. They set a “buy” rating and a $20.00 target price on the stock. Wall Street Zen raised Elicio Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. HC Wainwright raised their price target on Elicio Therapeutics from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Finally, Rodman & Renshaw raised Elicio Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Elicio Therapeutics by 186.8% during the 3rd quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock worth $39,000 after acquiring an additional 2,335 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Elicio Therapeutics in the 2nd quarter valued at about $46,000. Summit Financial LLC purchased a new stake in shares of Elicio Therapeutics in the fourth quarter worth approximately $80,000. HighTower Advisors LLC purchased a new stake in shares of Elicio Therapeutics in the fourth quarter worth approximately $89,000. Finally, Jane Street Group LLC acquired a new stake in shares of Elicio Therapeutics during the first quarter worth approximately $92,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Elicio Therapeutics Company Profile

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.